Safety and efficacy of oral Ketamine in resistant depressio
- Conditions
- Health Condition 1: F332- Major depressive disorder, recurrent severe without psychotic featuresHealth Condition 2: F330- Major depressive disorder, recurrent, mildHealth Condition 3: F331- Major depressive disorder, recurrent, moderateHealth Condition 4: F320- Major depressive disorder, singleepisode, mildHealth Condition 5: F321- Major depressive disorder, singleepisode, moderateHealth Condition 6: F322- Major depressive disorder, singleepisode, severe without psychotic features
- Registration Number
- CTRI/2023/06/054271
- Lead Sponsor
- Department of psychiatry
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1. All participants who have not responded adequately to therapeutic trials of 2 antidepressants of different classes given in adequate dose for 6 weeks.
2. Participants should be on stable medication of antidepressants for a period of at least 6 weeks.
3. Able to give informed consent.
1. Participants who have taken Ketamine treatment (in any route) for depression before.
2. Participants having any known gastrointestinal issues or oral ulcers or diseases.
3. Pregnant participants.
4. Participants with age <18.
5. Any other serious medical condition.
6. Any other associated psychiatric disorder.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Assessing Safety & efficacy of oral ketamine in treatment resistant depressionTimepoint: 10 VISITS <br/ ><br>1st week 3 visits <br/ ><br>2nd week 3 visits <br/ ><br>3rd week 2 visits <br/ ><br>4rth week 2 visits <br/ ><br>
- Secondary Outcome Measures
Name Time Method Assess improvement in treatment resistant depression with active suicidal ideationTimepoint: 10 visits <br/ ><br>1st week 3 visits <br/ ><br>2nd week 3 visits <br/ ><br>3rd week 2 visits <br/ ><br>4rth week 2 visits <br/ ><br>